EUVIMEDEUVIMED entdecken
Crossref

Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway

Kaibin Lin, Ai Wang, Changlin Zhai, Yun Zhao, Huilin Hu, Dong Huang, Qiwei Zhai, Yan Yan, Junbo Ge

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Kaibin Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetic Cardiomyopathies, Phosphatidylethanolamine Binding Protein, Myocardium. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Outstanding Youth Science Fund Project of National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) exert cardiovascular benefits in diabetic patients, but the underlying mechanisms remain incompletely understood. Semaglutide, a novel long‐acting GLP‐1RA, has shown a reduced risk of cardiovascular events. Based on these results, we investigated the therapeutic potential of semaglutide in diabetic cardiomyopathy and sought to elucidate the underlying mechanisms. Experimental Approach Mice with diabetes induced by high‐fat diet/streptozotocin were treated with semaglutide. The mechanisms underlying the cardioprotective effects of semaglutide were analysed using animal and cell experiments. Key Results In diabetic mice, semaglutide alleviated metabolic disorders, ameliorated myocardial fibrosis, improved cardiac function, antagonized oxidative stress and suppressed cardiomyocyte apoptosis. More significantly, semaglutide attenuated cardiac inflammation through restoring Raf kinase inhibitor protein (RKIP) expression and inhibiting downstream TANK‐binding kinase 1 (TBK1)‐NF‐κB pathway. Meanwhile, decreased RKIP expression and activated TBK1‐NF‐κB signalling pathway were also found in tissues from human diabetic hearts. RKIP deficiency exacerbated cardiac inflammation and offset the cardioprotective effect of semaglutide in diabetic mice. Moreover, semaglutide also restored the expression level of Sirtuin 3(Sirt3), which served as a modulator against cardiac inflammation by regulating RKIP‐dependent pathway. In diabetic mice, RKIP deficiency abolished the cardioprotective benefits conferred by the Sirt3 activator honokiol. We also found that cAMP/PKA signalling, rather than glucose lowering, contributed to the anti‐inflammatory effect of semaglutide through Sirt3‐dependent RKIP pathway. Conclusions and Implications Semaglutide exerted cardioprotective effects against diabetic heart failure by alleviating cardiac inflammation through Sirt3‐dependent RKIP signalling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDiabetic CardiomyopathiesPhosphatidylethanolamine Binding ProteinMyocardiumHeartHumansMaleAnimalsRandom AllocationDrug Evaluation, PreclinicalMice, Inbred C57BLCell LineFemaleMiddle AgedAgedRatsMice, KnockoutDiabetes Mellitus, ExperimentalInflammationMyocytes, CardiacOxidative StressMitochondria, HeartNF-kappa BSirtuinsSignal Transduction

Stichwörter der Autor:innen

RKIPdiabetes mellitusheart failureinflammationsemaglutide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsPhosphatidylethanolamine Binding ProteinNF-kappa BSirtuinsCyclic AMPCyclic AMP-Dependent Protein KinasesSemaglutideRaf kinase inhibitory protein, mouseTbk1 protein, mouseProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Cardiovascular Diseases, The Affiliated Hospital of Jiaxing University, Jiaxing, China.
  • Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Heart Center, Shanghai Jiaotong University Affiliated Sixth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
  • CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
  • School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Förderung

  • National Natural Science Foundation of China
  • National Outstanding Youth Science Fund Project of National Natural Science Foundation of China

Zitieren

APA

Lin, K., Wang, A., Zhai, C., Zhao, Y., Hu, H., Huang, D., Zhai, Q., Yan, Y., & Ge, J. (2025). Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway. British Journal of Pharmacology. https://doi.org/10.1111/bph.17327

Vancouver

Lin K, Wang A, Zhai C, Zhao Y, Hu H, Huang D, et al. Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway. British Journal of Pharmacology. 2025. doi:10.1111/bph.17327

BibTeX
@article{Lin2025,
  author = {Lin, Kaibin and Wang, Ai and Zhai, Changlin and Zhao, Yun and Hu, Huilin and Huang, Dong and Zhai, Qiwei and Yan, Yan and Ge, Junbo},
  title = {Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17327}
}
Kostenlos starten →